2m 2m 2m 2m 2m 2m 2m
Emergent BioSolu (EBS)
NYSE
$8.29$0.00 (0.00%)
Price as of Jun 15, 2026 7:40 PM EDT- $429.3MMarket Cap
- 32.85%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Emergent BioSolu (EBS)
$8.29$0.00 (0.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 705.2M -32.43% | 1.0B -0.54% | 1.0B -6.10% | 1.1B -37.66% | |
Cost of Revenue | 326.2M -74.68% | 1.3B +82.62% | 705.4M +1.77% | 693.1M -51.87% | |
Gross Profit | 379.0M +254.95% | -244.6M -177.02% | 317.6M -17.08% | 383.0M +8.62% | |
Sales and Marketing Expense | 186.1M -39.58% | 308.0M -16.40% | 368.4M +8.51% | 339.5M -2.55% | |
Research and Development Expense | -53.2M -24.75% | -70.7M -36.54% | -111.4M -40.84% | -188.3M -180.47% | |
Depreciation and Amortization Expense | 95.8M -11.95% | 108.8M -13.03% | 125.1M -12.70% | 143.3M +15.75% | |
Total Operating Expenses | 326.2M -74.68% | 1.3B +82.62% | 705.4M +1.77% | 693.1M -61.25% | |
Operating Profit | 100.1M +192.09% | -108.7M -85.04% | -726.4M +327.29% | -170.0M -148.21% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -87.9M +135.66% | -37.3M +8.12% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -87.9M +135.66% | -37.3M -208.12% | |
Total Nonoperating Income and Expense | -17.3M -49.42% | -34.2M +612.50% | -4.8M -90.20% | -49.0M +28.27% | |
Income before Taxes | 82.8M +157.94% | -142.9M -80.46% | -731.2M +233.88% | -219.0M -169.66% | |
Income Taxes | 30.2M -36.69% | 47.7M +62.80% | 29.3M +495.95% | -7.4M -108.86% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 52.6M +127.60% | -190.6M -74.94% | -760.5M +259.40% | -211.6M -191.64% | |
Net Income from Continuing Operations Applicable to Common | 82.8M +157.94% | -142.9M -80.46% | -731.2M +233.88% | -219.0M -169.66% | |
Basic EPS and Net Income | 0.98 +127.22% | -3.60 -75.76% | -14.85 +251.90% | -4.22 -197.69% | |
Diluted EPS and Net Income | 0.93 +125.83% | -3.60 -75.76% | -14.85 +251.90% | -4.22 -198.83% | |
Basic Weighted Average Shares | 53.5M +0.94% | 53.0M +3.52% | 51.2M +2.20% | 50.1M -6.36% | |
Diluted Weighted Average Shares | 56.7M +6.98% | 53.0M +3.52% | 51.2M +2.20% | 50.1M -7.39% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 205.4M +106.43% | 99.5M -10.92% | 111.7M -82.62% | 642.6M +11.54% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 205.4M +106.43% | 99.5M -10.92% | 111.7M -82.62% | 642.6M +11.54% | |
Total Current Assets | 662.5M +10.66% | 598.7M -11.89% | 679.5M -43.86% | 1.2B -4.85% | |
Accumulated Depreciation | 304.1M -23.42% | 397.1M -3.48% | 411.4M +7.19% | 383.8M +20.28% | |
Property and Plant and Equipment and Net | 205.4M -24.09% | 270.6M -29.31% | 382.8M -53.18% | 817.6M +2.19% | |
Total Long-Term Assets | 14.2M -24.87% | 18.9M -90.27% | 194.3M +1.57% | 191.3M +233.86% | |
Total Assets | 1.3B -5.12% | 1.4B -23.78% | 1.8B -42.42% | 3.2B +7.01% | |
Income Taxes Payable | 44.6M +6.95% | 41.7M -11.65% | 47.2M -20.94% | 59.7M -37.09% | |
Total Short-Term Debt | N/A N/A | 0 -100.00% | 413.7M -56.78% | 957.3M +2,929.43% | |
Total Current Liabilities | 132.2M -18.60% | 162.4M -75.07% | 651.3M -47.00% | 1.2B +228.76% | |
Total Long-Term Debt | 572.1M -13.80% | 663.7M +48.65% | 446.5M -0.45% | 448.5M -44.59% | |
Total Long-Term Liabilities | 53.9M +37.85% | 39.1M +35.29% | 28.9M -30.36% | 41.5M -21.25% | |
Total Liabilities | 796.0M -12.23% | 906.9M -22.74% | 1.2B -34.00% | 1.8B +32.73% | |
Retained Earnings | -159.8M -24.76% | -212.4M +874.31% | -21.8M -102.95% | 738.7M -22.88% | |
Total Stockholders Equity | 522.6M +8.24% | 482.8M -25.64% | 649.3M -53.21% | 1.4B -14.29% | |
Total Shares Outstanding | 52.1M -4.05% | 54.3M +4.02% | 52.2M +4.19% | 50.1M -2.34% | |
Cash Flow | |||||
Cash from Operating Activities | 170.6M +190.63% | 58.7M +128.45% | -206.3M +504.99% | -34.1M -110.62% | |
Capital Expenditures | 13.8M -39.74% | 22.9M -55.62% | 51.6M -55.44% | 115.8M -48.53% | |
Cash from Investing Activities | 69.4M -44.57% | 125.2M -41.03% | 212.3M +155.68% | -381.3M +69.47% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -136.6M -28.11% | -190.0M -64.53% | -535.7M -211.33% | 481.2M +441.28% | |
Financials Ratio | |||||
Gross Margin | 53.74% +329.30% | -23.44% -171.51% | 32.77% -13.70% | 37.98% +93.09% | |
Operating Margin | 14.19% +236.28% | -10.42% -84.95% | -69.23% +355.07% | -15.21% -177.34% | |
Return on Assets | 3.88% +132.74% | -11.86% -61.08% | -30.48% +341.22% | -6.91% -187.40% | |
Return on Equity | 10.46% +131.07% | -33.67% -54.90% | -74.67% +430.50% | -14.08% -193.45% | |
Revenue Growth | -32.43% +5,869.48% | -0.54% -91.10% | -6.10% -83.80% | -37.66% -346.87% | |
Current Ratio | 5.01 +35.93% | 3.69 +253.36% | 1.04 +5.93% | 0.98 -71.06% | |
Cash Ratio | 1.55 +153.58% | 0.61 +257.26% | 0.17 -67.20% | 0.52 -66.07% | |
Debt-to-Equity Ratio | N/A N/A | 1.37 +3.77% | 1.32 +30.78% | 1.01 +95.00% | |
Debt-to-Assets Ratio | N/A N/A | 0.48 +1.23% | 0.47 +6.26% | 0.44 +56.23% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow